This elegant double-blind, placebo-controlled trial shows the addition of an ARB in patients with ADPKD already on an ACE inhibitor did not alter the decline in estimated GFR. Based on this evidence, there seems to be no role for dual RAAS blockade in this population.
- Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
- The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis
- Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial